Genenta Announces Filing of Registration Statement for Proposed Initial Public Offering
November 10, 2021 17:30 ET
|
Genenta Science
MILAN, Italy and NEW YORK, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Genenta Science, a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene...
Genenta Strengthens Senior Management With Key Strategic Appointments
September 30, 2021 07:00 ET
|
Genenta Science
Gaurav Shah, Brad Loncar and Alec Ross appointed as strategic advisorsBarbara Regonini joins recently hired CFO, Richard Slansky, completing senior financial management team MILAN, Italy and NEW...
Genenta Appoints Four Renowned Oncology Experts to Scientific Advisory Board
May 17, 2021 04:33 ET
|
Genenta Science
MILAN, Italy and NEW YORK, May 17, 2021 (GLOBE NEWSWIRE) -- Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem cell gene therapy for cancer...
Genenta Phase I/II Glioblastoma Data at ASGCT Show Temferon™ Delivered Tumor-Focused Interferon Expression
May 14, 2021 01:30 ET
|
Genenta Science
MILAN, Italy and NEW YORK, May 14, 2021 (GLOBE NEWSWIRE) -- Genenta Science, a clinical-stage biotechnology company pioneering the development of an investigational hematopoietic stem progenitor...
Genenta to present at upcoming scientific congresses
May 10, 2021 01:30 ET
|
Genenta Science
MILAN, Italy and NEW YORK, May 10, 2021 (GLOBE NEWSWIRE) -- Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem cell gene therapy for cancer...
Genenta to Appoint Richard Slansky as CFO and Anthony Marucci as Board Member
May 03, 2021 01:30 ET
|
Genenta Science
MILAN, Italy and NEW YORK, May 03, 2021 (GLOBE NEWSWIRE) -- Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem cell gene therapy for cancer...
Genenta to Take Part in Gene Therapy Panel and Two Virtual Investor Events in January 2021
January 05, 2021 08:49 ET
|
Genenta Science
MILAN, Italy and NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem cell gene therapy for cancer...
Genenta to Appoint Stephen Squinto, Experienced Biotech Executive and Investor, as Chairman
November 23, 2020 01:00 ET
|
Genenta Science
MILAN, Italy and NEW YORK, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem progenitor cell gene therapy...
Genenta’s Temferon™: Evidence of Controlled and Targeted Interferon Expression in Preliminary Phase I/II Clinical Data in Glioblastoma Multiforme
November 16, 2020 01:00 ET
|
Genenta Science
MILAN, Italy and NEW YORK, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Genenta Science, a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene...
Genenta to present preliminary Phase I/II clinical data on Temferon™ in glioblastoma multiforme at Chardan’s 4th Annual Genetic Medicines Conference
September 30, 2020 08:51 ET
|
Genenta Science
MILAN, Italy and NEW YORK, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem cell gene therapy for cancer...